
Laura Ghezzi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1523849/publications.pdf Version: 2024-02-01



LALIDA CHEZZI

#	Article	IF	CITATIONS
1	Intermittent Fasting Confers Protection in CNS Autoimmunity by Altering the Gut Microbiota. Cell Metabolism, 2018, 27, 1222-1235.e6.	7.2	352
2	Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathologica, 2016, 131, 925-933.	3.9	262
3	Circulating miRNAs as Potential Biomarkers in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 1261-1267.	1.2	188
4	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer's and Dementia, 2016, 12, 154-163.	0.4	179
5	Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Multiple Sclerosis Journal, 2016, 22, 1061-1070.	1.4	97
6	Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neuropathologica, 2017, 133, 61-77.	3.9	72
7	Phenotypic Heterogeneity of the GRN Asp22fs Mutation in a Large Italian Kindred. Journal of Alzheimer's Disease, 2011, 24, 253-259.	1.2	62
8	Expression of the Transcription Factor Sp1 and its Regulatory hsa-miR-29b in Peripheral Blood Mononuclear Cells from Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 487-494.	1.2	61
9	Early Onset Behavioral Variant Frontotemporal Dementia due to the C9ORF72 Hexanucleotide Repeat Expansion: Psychiatric Clinical Presentations. Journal of Alzheimer's Disease, 2012, 31, 447-452.	1.2	60
10	Alterations of host-gut microbiome interactions in multiple sclerosis. EBioMedicine, 2022, 76, 103798.	2.7	59
11	Disease-modifying drugs in Alzheimer's disease. Drug Design, Development and Therapy, 2013, 7, 1471.	2.0	55
12	Inflammatory molecules in Frontotemporal Dementia: Cerebrospinal fluid signature of progranulin mutation carriers. Brain, Behavior, and Immunity, 2015, 49, 182-187.	2.0	51
13	Effects of dietary restriction on neuroinflammation in neurodegenerative diseases. Journal of Experimental Medicine, 2021, 218, .	4.2	47
14	Targeting the gut to treat multiple sclerosis. Journal of Clinical Investigation, 2021, 131, .	3.9	45
15	The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients. Multiple Sclerosis Journal, 2019, 25, 31-38.	1.4	39
16	Immunotherapy against amyloid pathology in Alzheimer's disease. Journal of the Neurological Sciences, 2013, 333, 50-54.	0.3	38
17	Alterations of the gut mycobiome in patients with MS. EBioMedicine, 2021, 71, 103557.	2.7	38
18	CSF β-amyloid and white matter damage: a new perspective on Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 352-357.	0.9	36

Laura Ghezzi

#	Article	IF	CITATIONS
19	Progranulin Gene Variability and Plasma Levels in Bipolar Disorder and Schizophrenia. PLoS ONE, 2012, 7, e32164.	1.1	34
20	Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. Alzheimer's Research and Therapy, 2018, 10, 46.	3.0	34
21	The Impact of Osteopontin Gene Variations on Multiple Sclerosis Development and Progression. Clinical and Developmental Immunology, 2012, 2012, 1-6.	3.3	31
22	A Novel MAPT Mutation Associated with the Clinical Phenotype of Progressive Nonfluent Aphasia. Journal of Alzheimer's Disease, 2011, 26, 19-26.	1.2	28
23	Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. Alzheimer's Research and Therapy, 2019, 11, 84.	3.0	28
24	Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF β-amyloid levels and brain volumes. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 280-287.	3.3	28
25	Evidence of CNS β-amyloid deposition in Nasu-Hakola disease due to the <i>TREM2</i> Q33X mutation. Neurology, 2017, 89, 2503-2505.	1.5	26
26	Cerebrospinal Fluid Level of Aquaporin4: A New Window on Glymphatic System Involvement in Neurodegenerative Disease?. Journal of Alzheimer's Disease, 2019, 69, 663-669.	1.2	21
27	The Gut Microbiome–Brain Crosstalk in Neurodegenerative Diseases. Biomedicines, 2022, 10, 1486.	1.4	20
28	Behavioral and Neurophysiological Effects of Transcranial Direct Current Stimulation (tDCS) in Fronto-Temporal Dementia. Frontiers in Behavioral Neuroscience, 2018, 12, 235.	1.0	19
29	CSF β-amyloid predicts prognosis in patients with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1223-1231.	1.4	19
30	A 66-year-old patient with vanishing white matter disease due to the p.Ala87Val <i>EIF2B3</i> mutation. Neurology, 2012, 79, 2077-2078.	1.5	16
31	Profiling of Ubiquitination Pathway Genes in Peripheral Cells from Patients with Frontotemporal Dementia due to C9ORF72 and GRN Mutations. International Journal of Molecular Sciences, 2015, 16, 1385-1394.	1.8	14
32	T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients. Multiple Sclerosis Journal, 2020, 26, 1172-1186.	1.4	13
33	Sciatic endometriosis presenting as periodic (catamenial) sciatic radiculopathy. Journal of Neurology, 2012, 259, 1470-1471.	1.8	12
34	Genetics and Expression Analysis of the Specificity Protein 4 Gene (SP4) in Patients with Alzheimer's Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2012, 31, 537-542.	1.2	9
35	Word and Picture Version of the Free and Cued Selective Reminding Test (FCSRT): Is There Any Difference?. Journal of Alzheimer's Disease, 2017, 61, 47-52.	1.2	8
36	The influence of hormonal contraception on depression and female sexuality: a narrative review of the literature. Gynecological Endocrinology, 2022, 38, 193-201.	0.7	8

Laura Ghezzi

#	Article	IF	CITATIONS
37	Balò's concentric sclerosis: still to be considered as a variant of multiple sclerosis?. Neurological Sciences, 2015, 36, 2277-2280.	0.9	7
38	The Novel GRN g.1159_1160delTG Mutation is Associated with Behavioral Variant Frontotemporal Dementia. Journal of Alzheimer's Disease, 2015, 44, 277-282.	1.2	7
39	P1-043: CIRCULATING AND INTRATHECAL MIRNAS AS POTENTIAL BIOMARKERS FOR ALZHEIMER'S DISEASE. , 2014, 10, P318-P319.		6
40	Inflammatory expression profile in peripheral blood mononuclear cells from patients with Nasu-Hakola Disease. Cytokine, 2019, 116, 115-119.	1.4	6
41	Low CSF β-amyloid levels predict early regional grey matter atrophy in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 39, 101899.	0.9	5
42	CSF β-amyloid predicts early cerebellar atrophy and is associated with a poor prognosis in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 37, 101462.	0.9	5
43	Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod. Journal of the Neurological Sciences, 2017, 381, 296-297.	0.3	4
44	Diagnosis of Alzheimerâ \in TM s Disease Typical and Atypical Forms. , 2018, , 21-28.		4
45	Monozygotic Twins with Frontotemporal Dementia Due To Thr272fs GRN Mutation Discordant for Age At Onset. Journal of Alzheimer's Disease, 2019, 67, 1173-1179.	1.2	4
46	Usefulness of Multi-Parametric MRI for the Investigation of Posterior Cortical Atrophy. PLoS ONE, 2015, 10, e0140639.	1.1	4
47	Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy. Immunotherapy, 2014, 6, 23-28.	1.0	3
48	Profiling of Specific Gene Expression Pathways in Peripheral Cells from Prodromal Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2018, 61, 1289-1294.	1.2	2
49	Detection of the SQSTM1 Mutation in a Patient with Early-Onset Hippocampal Amnestic Syndrome. Journal of Alzheimer's Disease, 2021, 79, 477-481.	1.2	2
50	Differentiating Vogt-Koyanagi-Harada syndrome from recurrent optic neuritis: a case report and review of the literature concerning Hispanic patients. Multiple Sclerosis and Demyelinating Disorders, 2017, 2, .	1.1	1
51	Alzheimer's Disease: Clinical Aspects and Treatments. , 2014, , 17-26.		1
52	P1-044: TREM2 GENETIC VARIABILITY IN PATIENTS WITH ALZHEIMER'S DISEASE AND FRONTOTEMPORAL LOBAR DEGENERATION. , 2014, 10, P319-P319.		0
53	Alterations of the Gut Mycobiome in Patients with MS. SSRN Electronic Journal, 0, , .	0.4	0
54	Dietary restriction in multiple sclerosis: evidence from preclinical and clinical studies. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 0, , .	0.1	0